
Activists seek early decision on better access to life-saving breast cancer medicine
The story in brief
After the original petitioner's death, the High Court continued the case suo motu, recognizing public interest. The working group, comprising patient advocates, legal experts, and healthcare professionals, urged action on life-saving breast cancer drugs like Ribociclib and Abemaciclib, costing ₹78,460.75 and ₹47,752–₹95,504 monthly. Generic versions, 90–95% cheaper, remain inaccessible due to patent protections.